Towards selectivity? Approaches to the design of new anti-tumour agents--I.
D000336:Aerosols; D000818:Animals; D000912:Antibodies, Neoplasm; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use; D055598:Chemical Phenomena; D002621:Chemistry; D002699:Chlorambucil / Q000378:metabolism; D003520:Cyclophosphamide / Q000378:metabolism / Q000627:therapeutic use; D004273:DNA, Neoplasm; D004789:Enzyme Activation; D005260:Female; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D009374:Neoplasms, Experimental / Q000188:drug therapy; D012334:RNA, Neoplasm; D013329:Structure-Activity Relationship; D014301:Trinitrobenzenes / Q000627:therapeutic use
D000336:Aerosols; D000912:Antibodies, Neoplasm; D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D012334:RNA, Neoplasm; D014301:Trinitrobenzenes; D002699:Chlorambucil; D003520:Cyclophosphamide